Back to top

Crescent Biopharma (CBIO) Gets a Buy from Wedbush

In a report released today, from Wedbush maintained a Buy rating on Crescent Biopharma, with a price target of $27.00. In addition to Wedbush, Cres...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Crescent Biopharma, Inc. (CBIO)